MX2023012124A - Conjugados de dominio fn3-arnip y usos de los mismos. - Google Patents

Conjugados de dominio fn3-arnip y usos de los mismos.

Info

Publication number
MX2023012124A
MX2023012124A MX2023012124A MX2023012124A MX2023012124A MX 2023012124 A MX2023012124 A MX 2023012124A MX 2023012124 A MX2023012124 A MX 2023012124A MX 2023012124 A MX2023012124 A MX 2023012124A MX 2023012124 A MX2023012124 A MX 2023012124A
Authority
MX
Mexico
Prior art keywords
domain
sirna conjugates
sirna
molecules
conjugates
Prior art date
Application number
MX2023012124A
Other languages
English (en)
Spanish (es)
Inventor
Steven G Nadler
Swapnil Kulkarni
Russell C Addis
Yao Xin
Zhanna Druzina
Karyn T O''neil
Robert V Kolakowski
Stephen J Anderson
Original Assignee
Aro Biotherapeutics Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aro Biotherapeutics Company filed Critical Aro Biotherapeutics Company
Publication of MX2023012124A publication Critical patent/MX2023012124A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2023012124A 2021-04-14 2022-04-14 Conjugados de dominio fn3-arnip y usos de los mismos. MX2023012124A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163174776P 2021-04-14 2021-04-14
US202163203776P 2021-07-30 2021-07-30
US202263324437P 2022-03-28 2022-03-28
PCT/US2022/024846 WO2022221550A1 (en) 2021-04-14 2022-04-14 Fn3 domain-sirna conjugates and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012124A true MX2023012124A (es) 2024-01-11

Family

ID=83640757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012124A MX2023012124A (es) 2021-04-14 2022-04-14 Conjugados de dominio fn3-arnip y usos de los mismos.

Country Status (11)

Country Link
US (2) US12239710B2 (enExample)
EP (1) EP4323008A4 (enExample)
JP (1) JP2024514266A (enExample)
KR (1) KR20240031947A (enExample)
AU (1) AU2022258584A1 (enExample)
BR (1) BR112023021318A2 (enExample)
CA (1) CA3215367A1 (enExample)
IL (1) IL307595A (enExample)
MX (1) MX2023012124A (enExample)
TW (1) TWI906502B (enExample)
WO (1) WO2022221550A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CN119604311A (zh) * 2022-04-14 2025-03-11 Aro生物疗法公司 FN3结构域-siRNA缀合物与酶替代疗法
WO2025231388A1 (en) * 2024-05-03 2025-11-06 Aro Biotherapeutics Company Methods and compositions for treating pompe disease
WO2025245474A1 (en) * 2024-05-23 2025-11-27 Aro Biotherapeutics Company Formulations comprising fn3-sirna conjugates and uses thereof

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
DE69329877T2 (de) 1992-05-07 2001-04-26 Affitech A/S, Oslo Von L Protein abgeleitete Immunoglobulin-bindende Proteine und deren anwendungen
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5691157A (en) 1995-10-24 1997-11-25 The Research Foundation Of State University Of New York Method for detecting a mammal's prior exposure to radiation or radiomimetic chemicals
US5846456A (en) 1996-01-17 1998-12-08 National Science Council Method of making gradient index optical element
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6846655B1 (en) 1998-06-29 2005-01-25 Phylos, Inc. Methods for generating highly diverse libraries
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
GB0119476D0 (en) 2001-08-09 2001-10-03 Novartis Forschungsstiftlung Z Anti-tumour agents and method of identifying anti-tumour agents
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
WO2003104418A2 (en) 2002-06-06 2003-12-18 Research Corporation Technologies, Inc. Reconstituted polypeptides
DK1534830T3 (da) 2002-09-06 2011-02-14 Isogenica Ltd In vito-peptid-ekspressionsbibliotek
WO2004029224A2 (en) 2002-09-30 2004-04-08 Compound Therapeutics, Inc. Methods of engineering spatially conserved motifs in polypeptides
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
WO2004093892A2 (en) 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
WO2005018534A2 (en) 2003-05-16 2005-03-03 Rosetta Inpharmatics, Llc Methods and compositions for rna interference
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN1926551B (zh) 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co INHIBITORS OF TYPE-2 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS
US20080220049A1 (en) 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US20060040278A1 (en) 2004-01-27 2006-02-23 Cojocaru Gad S Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
SG134283A1 (en) 2006-01-24 2007-08-29 Ind Tech Res Inst Biomarkers for liver fibrotic injury
RU2429014C2 (ru) 2006-03-31 2011-09-20 Массачусетс Инститьют Оф Текнолоджи Лечение опухолей, экспрессирующих мутантные рецепторы egf
FR2903987B1 (fr) 2006-07-21 2012-12-21 Centre Nat Rech Scient Nouveaux derives de cyclodextrines amphiphiles, leur utilisation dans les domaines pharmaceutiques,cosmetiques, alimentaires et leur application a la production de nouveaux nanosystemes
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
WO2008079973A2 (en) 2006-12-21 2008-07-03 Centocor, Inc. Egfr binding peptides and uses thereof
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ（アミノ酸）ターゲッティング部分
AU2008239594B2 (en) 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
EP2144930A1 (en) 2007-04-18 2010-01-20 ZymoGenetics, Inc. Single chain fc, methods of making and methods of treatment
ES2310122B1 (es) 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008156642A1 (en) 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
CA2700410C (en) 2007-10-03 2020-10-06 Cornell University Treatment of proliferative disorders using antibodies to psma
US8633297B2 (en) 2007-10-31 2014-01-21 Medimmune, Llc Protein scaffolds
WO2009073809A2 (en) 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
WO2009085468A2 (en) 2007-12-19 2009-07-09 Centocor, Inc. Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
EP2238247A2 (en) 2007-12-19 2010-10-13 Centocor Ortho Biotech Inc. Alternative scaffold protein fusions phage display via fusion to plx of m13 phage
WO2009083804A2 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
KR20100135780A (ko) 2008-03-06 2010-12-27 제넨테크, 인크. Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법
CL2009000843A1 (es) 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
EA201001734A1 (ru) 2008-05-02 2011-10-31 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009142773A2 (en) 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
JP2012504606A (ja) 2008-10-01 2012-02-23 ラディック インスティテュート フォー キャンサー リサーチ 癌の治療方法
EP2349327A4 (en) 2008-10-23 2012-11-28 Massachusetts Inst Technology COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
BRPI1008532B1 (pt) 2009-02-12 2021-12-14 Janssen Biotech, Inc Arcabouço de proteína isolada, método para construção de uma biblioteca de arcabouço de proteína isolada, molécula de ácido nucleico isolada, vetor de ácido nucleico isolado, célula hospedeira de bactéria ou fungo, composição, dispositivo médico e artigo de manufatura para uso farmacêutico ou de diagnóstico em seres humanos
WO2010115202A2 (en) 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
CN103555722B (zh) 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
EP2417164A1 (en) 2009-04-07 2012-02-15 Roche Glycart AG Bispecific anti-erbb-2/anti-c-met antibodies
EP2452165A1 (en) 2009-07-07 2012-05-16 Siemens AG Apparatus and method for measuring multi-phase fluid flow
WO2011020033A2 (en) 2009-08-13 2011-02-17 Massachusetts Institute Of Technology Engineered proteins including mutant fibronectin domains
KR101237036B1 (ko) * 2009-11-04 2013-02-25 성균관대학교산학협력단 안티센스 가닥에 의한 오프-타겟 효과를 최소화한 신규한 ｓｉＲＮＡ 구조 및 그 용도
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011100700A2 (en) 2010-02-12 2011-08-18 University Of Rochester Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
WO2011130324A1 (en) 2010-04-13 2011-10-20 Medimmune, Llc Fibronectin type iii domain-based multimeric scaffolds
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
US8569227B2 (en) 2010-04-30 2013-10-29 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US20130273561A1 (en) 2010-10-29 2013-10-17 The Governing Council Of The University Of Toronto Lipid encapsulation of surface enhanced raman scattering (sers) nanoparticles
WO2012162418A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
US20120315639A1 (en) 2011-06-08 2012-12-13 Glenn Yaguang Deng Method and apparatus for single cell isolation and analysis
JP6440496B2 (ja) 2011-09-27 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
AU2012358238B2 (en) 2011-12-22 2017-12-07 C. Frank Bennett Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
JP6060178B2 (ja) 2012-01-05 2017-01-18 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
EP2852380A4 (en) 2012-05-23 2016-01-20 Univ Ohio State LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
CN104470944B (zh) 2012-05-25 2021-09-14 詹森生物科技公司 非天然共有白蛋白结合结构域
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
WO2014025828A1 (en) 2012-08-06 2014-02-13 The Regents Of The University Of California Engineered antibody fragments for targeting and imaging cd8 expression in vivo
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
MX361088B (es) 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9433689B2 (en) 2013-03-12 2016-09-06 The Board Of Trustees Of The Leland Stanford Junio Probes and methods of imaging non-Hodgkins lymphoma
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP3594240B1 (en) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
WO2015048724A1 (en) 2013-09-30 2015-04-02 The University Of North Carolina At Chapel Hill Methods and compositions for self-assembly system of nanoparticles and microparticles for multi-targeting specificity
BR112016008125B1 (pt) 2013-10-14 2023-11-21 Janssen Biotech, Inc. Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína
EP3060581A4 (en) 2013-10-25 2017-06-07 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
CA2932819A1 (en) 2013-12-09 2015-06-18 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
PL3094351T3 (pl) 2014-01-15 2022-06-27 Kadmon Corporation, Llc Środki immunomodulujące
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
ES2736127T3 (es) 2014-03-20 2019-12-26 Bristol Myers Squibb Co Dominios de tipo III de fibronectina de unión a seroalbúmina
AU2015243535A1 (en) 2014-04-08 2016-11-03 University Of Southern California Polypeptide compositions with Type VII collagen fibronectin Type Ill- like repeats and treatment methods for wound closure and healing
JP6666905B2 (ja) 2014-05-29 2020-03-18 スプリング バイオサイエンス コーポレーション Ｐｄ−ｌ１抗体及びその使用
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
WO2016004043A1 (en) 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded RNA materials and their uses
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
CA2969067A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
EP3291836A4 (en) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
US10844111B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type III domains
JP2018517708A (ja) 2015-06-05 2018-07-05 ニューヨーク・ユニバーシティ 抗ブドウ球菌生物学的薬剤のための組成物及び方法
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
CN105907719B (zh) 2016-04-18 2019-10-18 阿思科力(苏州)生物科技有限公司 Anti ROBO1 CAR-T细胞及其制备和应用
SG11201810687SA (en) 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
AU2017286811A1 (en) * 2016-06-17 2018-11-22 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
DK3473270T5 (da) * 2016-06-20 2024-09-09 Genahead Bio Inc Konjugat af antistof-lægemiddel
MA45412A (fr) 2016-06-21 2021-05-26 Janssen Biotech Inc Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine
MA46236A (fr) 2016-09-14 2019-07-24 Janssen Biotech Inc Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
IL268417B2 (en) * 2017-02-10 2025-05-01 Univ Rockefeller Methods for cell-type specific profiling to identify drug targets
CA3082204A1 (en) 2017-12-13 2019-06-20 Janssen Biotech, Inc. Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
MX2020011570A (es) * 2018-05-07 2020-11-24 Alnylam Pharmaceuticals Inc Administracion extrahepatica.
AR115847A1 (es) * 2018-07-25 2021-03-03 Ionis Pharmaceuticals Inc Compuestos y métodos para reducir la expresión de la atxn2
WO2021030763A1 (en) 2019-08-15 2021-02-18 Ionis Pharmaceuticals, Inc. Modified oligomeric compounds and uses thereof
KR20220062517A (ko) 2019-08-15 2022-05-17 아이오니스 파마수티컬즈, 인코포레이티드 결합 변형된 올리고머 화합물 및 이의 용도
CN119119240A (zh) 2019-10-14 2024-12-13 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021226107A1 (en) 2020-05-05 2021-11-11 Avidity Biosciences, Inc. Compositions and methods of treating pompe disease
AU2022239717A1 (en) 2021-03-15 2023-11-02 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
EP4314016A1 (en) 2021-03-31 2024-02-07 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
EP4323008A4 (en) 2021-04-14 2026-02-25 Aro Biotherapeutics Company FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES
CA3214552A1 (en) * 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
CN119604311A (zh) 2022-04-14 2025-03-11 Aro生物疗法公司 FN3结构域-siRNA缀合物与酶替代疗法
EP4519440A2 (en) 2022-05-06 2025-03-12 ARO Biotherapeutics Company Compositions and methods for gys1 inhibition

Also Published As

Publication number Publication date
JP2024514266A (ja) 2024-03-29
TW202304519A (zh) 2023-02-01
KR20240031947A (ko) 2024-03-08
BR112023021318A2 (pt) 2023-12-19
WO2022221550A1 (en) 2022-10-20
US20220370626A1 (en) 2022-11-24
US20250281622A1 (en) 2025-09-11
AU2022258584A1 (en) 2023-10-12
EP4323008A4 (en) 2026-02-25
EP4323008A1 (en) 2024-02-21
TWI906502B (zh) 2025-12-01
US12239710B2 (en) 2025-03-04
IL307595A (en) 2023-12-01
CA3215367A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
MX2023012124A (es) Conjugados de dominio fn3-arnip y usos de los mismos.
ECSP18062538A (es) Conjugado de enzimas terapéuticas
CL2019002590A1 (es) Compuestos de dinucleótidos cíclicos modificados.
MX2023001582A (es) Conjugados proteina-polimero-farmaco.
MX2016004596A (es) Conjugados de proteina-polimero-farmaco.
CO2019009365A2 (es) Anticuerpos anti-lag3
TR201903066T4 (tr) E. colı'de enzimatik konjugasyonla rekombinant aşı üretimi.
JOP20190066A1 (ar) مركبات حلقية ثنائية النيوكليوتيد
CL2018002895A1 (es) Moléculas de unión b7-h3 novedosas, conjugados anticuerpo-fármaco de los mismos y métodos de uso de los mismos
CO6710907A2 (es) Anticuerpos que se unen específicamente a cd33 que son útiles en el tratamiento de trastornos de células mieloides y del síndrome mielodisplásico (msd)
MX375715B (es) Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos.
EA201890389A2 (ru) Композиции конъюгата xten и способы их получения
EA201791461A1 (ru) Бензодиазепиновые димеры с мостиковым гетероариленом, их конъюгаты, способы получения и применение
MX392977B (es) Composiciones y metodos para programar celulas terapeuticas utilizando nanoportadores de acidos nucleicos dirigidos.
WO2021076574A3 (en) Fn3 domain-sirna conjugates and uses thereof
MX2015015264A (es) Composiciones y metodos para modular la expresion de ttr y vhb.
CL2019002135A1 (es) Células microbianas, métodos para producir las mismas, y usos de las mismas.
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
MX2019009428A (es) Conjugados de pirrolobenzodiazepinas y anticuerpos.
BR112015018504A2 (pt) moduladores de flap
CL2021002574A1 (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
UY32943A (es) Cultivar de arroz denominado "cl111"
CR20110333A (es) Hibridos y cultivares derivados del cultivar de arroz designado como cl151
MX2022006132A (es) Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
MX2025004572A (es) Conjugados de dominio fn3-arnip y usos de estos